We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Polyplus-transfection Licenses Roche Glycart AG for PEI in vitro Transfection Applications for Research Purposes
News

Polyplus-transfection Licenses Roche Glycart AG for PEI in vitro Transfection Applications for Research Purposes

Polyplus-transfection Licenses Roche Glycart AG for PEI in vitro Transfection Applications for Research Purposes
News

Polyplus-transfection Licenses Roche Glycart AG for PEI in vitro Transfection Applications for Research Purposes

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Polyplus-transfection Licenses Roche Glycart AG for PEI in vitro Transfection Applications for Research Purposes"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

By entering into this license agreement, Roche Glycart AG becomes one of Polyplus’ sub-licensees for the use of PEI-mediated transfection applications for research purposes. This license will enable Roche Glycart AG to use this world-recognized transfection reagent in its research to produce antibody-based products.

“We are delighted to sign this license agreement with Roche Glycart AG, an innovative subsidiary of Roche, focused in the research and development of new engineered antibody-based products,” said Mark Bloomfield, CEO of Polyplus-transfection. “PEI-mediated transfection is clearly an essential research tool in this field. Our business relationship with Roche Glycart AG also demonstrates the significant value of our intellectual property rights in the field of PEI-mediated nucleic acid delivery for research purposes.”

Financial terms were not disclosed.

Advertisement